Biopanning of Phage Displayed Peptide Libraries for the Isolation of Cell-Specific Ligands

Division of Translational Research, Department of Internal Medicine and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Methods in Molecular Biology (Impact Factor: 1.29). 02/2009; 504:291-321. DOI: 10.1007/978-1-60327-569-9_18
Source: PubMed


One limitation in the development of biosensors for the early detection of disease is the availability of high specificity and affinity ligands for biomarkers that are indicative of a pathogenic process. Within the past 10 years, biopanning of phage displayed peptide libraries on intact cells has proven to be a successful route to the identification of cell-specific ligands. The peptides selected from these combinatorial libraries are often able to distinguish between diseased cells and their normal counterparts as well as cells in different activation states. These ligands are small and chemical methodologies are available for regiospecific derivatization. As such, they can be incorporated into a variety of different diagnostic and therapeutic platforms. Here we describe the methods utilized in the selection of peptides from phage displayed libraries by biopanning. In addition, we provide methods for the synthesis of the selected peptides as both monomers and tetramers. Downstream uses for the peptides are illustrated.

Download full-text


Available from: Michael Joseph Mcguire, Oct 12, 2015
1 Follower
345 Reads
  • Source
    • "Phage display is useful for identifying peptides that bind cell surface features678. Affinity selection (biopanning) on intact cells is a versatile approach for identifying ligands, and this approach has yielded targeting peptides9101112131415. Yet, there have not been concerted efforts to generate panels of tumor targeting peptides nor has there been a focus on translating the peptides into high affinity ligands outside of the context of the phage. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor targeting ligands are emerging components in cancer therapies. Widespread use of targeted therapies and molecular imaging is dependent on increasing the number of high affinity, tumor-specific ligands. Towards this goal, we biopanned three phage-displayed peptide libraries on a series of well-defined human non-small cell lung cancer (NSCLC) cell lines, isolating 11 novel peptides. The peptides show distinct binding profiles across 40 NSCLC cell lines and do not bind normal bronchial epithelial cell lines. Binding of specific peptides correlates with onco-genotypes and activation of particular pathways, such as EGFR signaling, suggesting the peptides may serve as surrogate markers. Multimerization of the peptides results in cell binding affinities between 0.0071-40 nM. The peptides home to tumors in vivo and bind to patient tumor samples. This is the first comprehensive biopanning for isolation of high affinity peptidic ligands for a single cancer type and expands the diversity of NSCLC targeting ligands.
    Scientific Reports 03/2014; 4:4480. DOI:10.1038/srep04480 · 5.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Targeted cancer therapies focus on molecular and cellular changes that are specific to cancer and hold the promise of harming fewer normal cells, reducing side effects, and improving the quality of life. One major challenge in cancer nanotechnology is how to selectively deliver nanoparticles to diseased tissues while simultaneously minimizing the accumulation onto the nanoparticle of unwanted materials (e.g., proteins in the blood) during the delivery process. Once therapeutic nanoparticles have been created, very often they are linked or coated to other molecules that assist in targeting the delivery of nanoparticles to different cell types of the body. These linkers or coatings have been termed targeting ligands or “smart molecules” because of their inherent ability to direct selective binding to cell types or states and, therefore, confer “smartness” to nanoparticles. Likewise, “smartness” can be imparted to the nanoparticles to selectively repel unwanted entities in the body. To date, such smart molecules can consist of peptides, antibodies, engineered proteins, nucleic acid aptamers, or small organic molecules. This review describes how such smart molecules are discovered, enhanced, and anchored to nanoparticles, with an emphasis on how to minimize nonspecific interactions of nanoparticles to unintended targets.
    06/2009; 34(06). DOI:10.1557/mrs2009.119
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mistletoe lectins (MLs) are the active components of aqueous mistletoe extracts widely used in complementary cancer therapy, however, it is not clear if they bind to carbohydrate residues only or whether they interact with proteins as well. Protein-protein interactions do not seem unlikely as MLs act at very low molar concentrations usually observed with peptide-peptide interactions only and not seen with lectin-sugar interactions. In order to detect protein-protein interactions a random peptide library was screened for the ability to bind to MLs. MLs bound to peptides showing homologies to multidrug resistance-associated protein 5 (MRP5). However, the MLs only slightly modified the MRP5 efflux pump, while periodate treatment to inhibit cell membrane binding via glycan completely abolished the ML-I binding sites in MRP5 overexpressing cells. The protein sequence is not important for ML-I binding, indicating that the biological activity of MLs can most likely be attributed to the sugar chains.
    Anticancer research 12/2009; 29(12):4941-8. · 1.83 Impact Factor
Show more